吉林阴茎白色分泌物怎么治疗吉林包皮的手术方法,吉林去医院做包皮挂什么科,吉林男性生殖器流白色分泌物,吉林前列腺炎引起睾丸疼怎么办,吉林包皮长环赘生物怎么治疗,吉林前列腺钙化会影响生育吗,吉林怎么才能治疗早泄

VIENNA, Aug. 11 (Xinhua) -- Austrian researchers have developed a method of using fungi and produced enzymes to split Polyethylene Terephthalate (PET) material into their initial state, enabling the recovery of all individual components, said the Austrian Center of Industrial Biotechnology (ACIB) Thursday in a press release.Enzyme is a special protein that acts as biological catalyst, for example, bacteria and fungi in the nature can break down long chain molecules.Researchers from the Technical University of Graz, the Technical University of Vienna and the Agricultural University of Vienna jointly found that efficient enzymes are capable to break and split PET into small fragments.With different methods, the researchers forced the fungi to overproduce their precious "split-tools" after they are modified and improved by genetic engineering.Through the new method developed by the ACIB, it is now possible to decompose the PET polymer to its initial monomers with high product quality and from this to produce new high-quality materials again.This circuit avoids waste and thus saves resources and is friendly to the environment, said Geog Guebitz, head of the Research Department on Enzymes and Polymers in the ACIB.He further explained that the ACIB has established a partnership with some industrial enterprises to carry out application experiments. From the current splitting time of 24 hours, the researchers expect to shorten the whole process to "a few hours," he added.PET is a common plastic material in the polyester family, widely used in the textile industry. PET film is mainly used in electrical insulation materials, which can be also used for production of film, X-ray films and computer taps, even to produce plastic bottle and other blow molding products.

BEIJING, Aug 4 (Xinhuanet) – A new urine test might help doctors detect prostate cancer and better evaluate a patient's treatment options, according to American reseachers Thursday."This is a tool that men and their physician can use to help them decide whether it's appropriate to get a biopsy now or delay that decision," said lead researcher Dr. Scott Tomlins, a pathology resident at the University of Michigan Health System.The test looks for two genetic markers associated with prostate cancer. The first, called TMPRSS2:ERG, is caused by two genes changing places and fusing together; it is thought to cause prostate cancer. Since the gene fusion is only seen in about half of cancer patients, the test also looks for another marker, called PCA3."We are exploiting some new bio-markers to try to refine the PSA (prostate-specific antigen) test," Tomlins said.

BEIJING, Sept. 6 (Xinhuanet) -- Scientists from Tufts University of the U.S. have created the world's smallest electrical motor in a single molecule.The finding was published in the journal Nature Nanotechnology on Monday.In the research, scientist successfully made a single molecule accept an electrical charge and rotate as fast as 120 revolutions per second."This is the first time that electrically-driven molecular motors have been demonstrated, despite a few theoretical proposals," said Charles H. Sykes, professor of chemistry at Tufts who led the team.The single molecule electric motor could lead to new types of electrical circuitry, giving hope for scientists to apply it in medicine and engineering, he said."The next thing to do is to couple it to other molecules, lining them up next to one another so they're like miniature cog-wheels, and then watch the rotation propagation down the chain," said Sykes.

BEIJING, Sept. 20 (Xinhuanet)-- Google's executive chairman Eric Schmidt is to face a Senate hearing on whether the company is abusing its dominance in Internet search, according to media reports on Tuesday.At the Wednesday's hearing before the Senate Judiciary Committee's antitrust panel, Schmidt will argue that critics are wrong to say Google gives preference to its own products, instead, Google is just trying to deliver the best-cultivated search results for users. The issue of search ranking is a touchy subject with Google, which says its algorithm is devised to give users the most useful result so they will come back.Another focal point of the hearing, which Schmidt concerned most is "scrapers", those who game its search algorithm, for example, taking commonly searched words, combine them into a nonsensical block of text and throw it up on the Web to grab eyeballs and advertising dollars.Google believes that, if scrapers succeed too often, consumers will lose confidence in search and turn to other resources, thus posing an existential threat to the company.Regulators in the U.S. and abroad have been looking into various aspects of Google's business practices since the company's 2007 purchase of ad firm DoubleClick. At the moment, European regulators are conducting an antitrust inquiry into Google's search business while the Federal Trade Commission is doing likewise. Google relies overwhelmingly on its core product, Internet search, and dominates the market for that product. It handles around two-thirds of U.S. Internet searches and more than 80 percent in many European countries, according to comScore Inc.

BEIJING, Sep. 13 (Xinhuanet) --Experts have called for a national drug-control system after a nationwide deficit of a life-saving drug, which has lasted at least three months.Doctors at a Beijing hospital said some specialized hospitals, which perform hundreds of cardiac operations every month, have been paralyzed by their lack of protamine sulfate, which is commonly administered after heart surgery to reverse the anticoagulant effects of heparin.The earliest report of a shortage was in Hubei province on July 21. This was followed by reports of shortages in Guangdong, Shandong and Liaoning provinces.The Shandong newspaper, Qilu Evening News, quoted a regional sales manager, surnamed Zhuang, as saying the province had been allocated 150 doses of protamine sulfate after Shanghai No 1 Biochemical and Pharmaceutical Co Ltd recently resumed production of the drug."But its monthly use here is usually 10,000 doses," he said.The Ministry of Health has denied it is responsible for supplies of the drug and passed the buck to the State Food and Drug Administration, claiming the latter is responsible for the supervision of medicines.Shen Chen, head of the publicity office of the State Food and Drug Administration, said he was unaware of the shortage, but said the administration is responsible for the quality of medicines, not the supply."Development and reform authorities oversee the medicines' prices, while the industrial and commercial authorities oversee the storage. The food and drug departments only cover the approval and quality of medicines."Industry insiders said one of the reasons for the shortage was the low profit margin, which discourages companies from mass producing the drug."Some companies can't earn enough to recover their costs, therefore it is almost impossible to maintain their enthusiasm for continuing production," said Lu Guoping, secretary-general of the Shanghai Pharmaceutical Trade Association.Lu said the government should issue policies to prevent future shortages of such medicines to avoid possible nationwide public health incidents.Yi Shenghua, a lawyer at Beijing Yingke Law Firm, said the country should have a unified system to guarantee the normal supply of medicines that are widely used and drug manufacturers should fulfill their responsibilities to society, even though there is no law stipulating they should produce specific medicines.He came up with two ways to deal with the problem of companies only producing profitable drugs."The government can order businesses to manufacture a certain amount of cheap medicines. Or it can offer financial assistance to subsidize cheap, but life-saving medicines."